Search

Your search keyword '"Mok, T.S.K."' showing total 21 results
Start Over Author "Mok, T.S.K." Topic non-small-cell lung carcinoma
21 results on '"Mok, T.S.K."'

2. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC.

Author

Mok, T.S.K., Lopes, G., Cho, B.C., Kowalski, D.M., Kasahara, K., Wu, Y.-L., de Castro, G., Turna, H.Z., Cristescu, R., Aurora-Garg, D., Loboda, A., Lunceford, J., Kobie, J., Ayers, M., Pietanza, M.C., Piperdi, B., and Herbst, R.S.

Subjects
*CLINICAL trials, *TREATMENT effectiveness, *NON-small-cell lung carcinoma, *PEMBROLIZUMAB, *CANCER chemotherapy
Abstract

We evaluated whether tissue tumor mutational burden (tTMB) and STK11 , KEAP1 , and KRAS mutations have clinical utility as biomarkers for pembrolizumab monotherapy versus platinum-based chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) advanced/metastatic non-small-cell lung cancer (NSCLC) without EGFR / ALK alterations in the phase III KEYNOTE-042 trial. This retrospective exploratory analysis assessed prevalence of tTMB and STK11 , KEAP1 , and KRAS mutations determined by whole-exome sequencing of tumor tissue and matched normal DNA and their associations with outcomes in KEYNOTE-042. Clinical utility of tTMB was assessed using a prespecified cut point of 175 mutations/exome. Of 793 patients, 345 (43.5%) had tTMB ≥175 mutations/exome and 448 (56.5%) had tTMB <175 mutations/exome. No association was observed between PD-L1 expression and tTMB. Continuous tTMB score was associated with improved overall survival (OS) and progression-free survival among patients receiving pembrolizumab (Wald test, one-sided P < 0.001) but not those receiving chemotherapy (Wald test, two-sided P > 0.05). tTMB ≥175 mutations/exome was associated with improved outcomes for pembrolizumab versus chemotherapy, whereas tTMB <175 mutations/exome was not {OS: hazard ratio, 0.62 [95% confidence interval (CI) 0.48-0.80] and 1.09 (95% CI 0.88-1.36); progression-free survival: 0.75 (0.59-0.95) and 1.27 (1.04-1.55), respectively}. Improved OS [hazard ratio (95% CI)] for pembrolizumab versus chemotherapy was observed regardless of STK11 [ STK11 mutant (n = 33): 0.37 (0.16-0.86), STK11 wild-type (n = 396): 0.83 (0.65-1.05)]; KEAP1 [ KEAP1 mutant (n = 64): 0.75 (0.42-1.35), KEAP1 wild-type (n = 365): 0.78 (0.61-0.99)], or KRAS [ KRAS mutant (n = 69): 0.42 (0.22-0.81); KRAS wild-type (n = 232): 0.86 (0.63-1.18)] mutation status. tTMB with a cut point of ≥175 mutations/exome is a potential predictive biomarker for pembrolizumab monotherapy for advanced/metastatic PD-L1 tumor proportion score ≥1% NSCLC. Pembrolizumab is a standard first-line treatment in this setting regardless of STK11 , KEAP1 , or KRAS mutation status. • Pembrolizumab monotherapy is a standard first-line treatment of patients with PD-L1-positive advanced/metastatic NSCLC. • We assessed clinical utility of potential biomarkers among patients receiving pembrolizumab versus chemotherapy. • tTMB ≥175 mutations/exome was associated with improved outcomes among patients receiving pembrolizumab versus chemotherapy. • tTMB has potential clinical utility as a biomarker for pembrolizumab in first-line PD-L1-positive advanced/metastatic NSCLC. • Pembrolizumab improved overall survival versus chemotherapy regardless of STK11 , KEAP1 , or KRAS mutation status. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. 585P Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib.

Author

Mok, T.S.K., Liu, G., Nyaw, S.F., Curcio, H., Cortot, A., Kam, T.Y., Descourt, R., Chik, Y.K., Cheema, P.K., Gwinnutt, J.M., Churchill, E.N., Nyborn, J., Curran, E., Yin, Y., Chong, K., Tanaka-Chambers, Y., Kretz, J., and Cadranel, J.

Subjects
*NON-small-cell lung carcinoma, *INSERTION mutation, *EPIDERMAL growth factor receptors, *TREATMENT effectiveness
Published
2023
Full Text
View/download PDF

4. 1361P Alectinib for treatment-naïve advanced ALK+ NSCLC selected via blood-based NGS: Updated analyses of outcomes, circulating tumour (ct)DNA and biomarker subgroups from BFAST Cohort A.

Author

Gadgeel, S.M., Mok, T.S.K., Peters, S., Nadal, E., Han, J-Y., Alatorre Alexander, J.A., Leighl, N., Sriuranpong, V., Pérol, M., Castro, G.D., de Marinis, F., Tan, D.S.W., Paul, S., Assaf, Z.J., MacLennan, M., Lohmann, T.O., Slade, M., Mathisen, M.S., Bhagawati-Prasad, V., and Dziadziuszko, R.

Subjects
*CIRCULATING tumor DNA, *NON-small-cell lung carcinoma, *BIOMARKERS, *DNA, *TUMORS
Published
2023
Full Text
View/download PDF

5. LBA4 CANOPY-N: A phase II study of canakinumab (CAN) or pembrolizumab (PEM), alone or in combination, as neoadjuvant therapy in patients (pts) with resectable stage Ib–IIIa non-small cell lung cancer (NSCLC).

Author

Mok, T.S.K., Pujol, J-L., Tsuboi, M., Lee, J., Kim, E., Leonov, O., Zhang, J., Duan, J., Lobetti-Bodoni, C., Brase, J.C., Savchenko, A., and Garrido Lopez, P.

Subjects
*NON-small-cell lung carcinoma, *NEOADJUVANT chemotherapy, *PEMBROLIZUMAB
Published
2022
Full Text
View/download PDF

6. LBA8 Nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with EGFR-mutated metastatic non-small cell lung cancer (mNSCLC) with disease progression after EGFR tyrosine kinase inhibitors (TKIs) in CheckMate 722.

Author

Mok, T.S.K., Nakagawa, K., Park, K., Ohe, Y., Girard, N., Kim, H.R., Wu, Y-L., Gainor, J., Lee, S-H., Chiu, C-H., Sang-We, K., Cheng-Ta, Y., Liang, W., Wu, L., Lin, M-C., Samol, J., Zhang, X., Sylvester, J., Li, S., and Yang, J.C-H.

Subjects
*NON-small-cell lung carcinoma, *PROTEIN-tyrosine kinase inhibitors, *NIVOLUMAB, *DISEASE progression, *EPIDERMAL growth factor receptors
Published
2022
Full Text
View/download PDF

10. LBA57 Adagrasib (ADA) vs docetaxel (DOCE) in patients (pts) with KRASG12C-mutated advanced NSCLC and baseline brain metastases (BM): Results from KRYSTAL-12.

Author

Barlesi, F., Yao, W., Duruisseaux, M., Doucet, L., Shi, J., Juan Vidal, O.J., Kim, Y-C., García Campelo, M.R., Azkárate Martínez, A., Lu, S., Jotte, R., Felip, E., Lo Russo, G., Reck, M., Zhang, Y., Hu, N., Michenzie, M.F., and Mok, T.S.K.

Subjects
*DOCETAXEL, *NON-small-cell lung carcinoma
Published
2024
Full Text
View/download PDF

12. 507O EXCLAIM-2: Phase III trial of first-line (1L) mobocertinib versus platinum-based chemotherapy in patients (pts) with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins)+ locally advanced/metastatic NSCLC.

Author

Jänne, P.A., Wang, B-C., Cho, B.C., Zhao, J., Li, J., Hochmair, M.J., Peters, S., Besse, B., Kato, T., Wu, Y-L., Nguyen, D., Lin, J., Vranceanu, F., Lin, M., Fram, R.J., and Mok, T.S.K.

Subjects
*EPIDERMAL growth factor receptors, *CLINICAL trials, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2023
Full Text
View/download PDF

15. 362P Intracranial activity of dacomitinib in treatment naïve advanced EGFR mutated non-small cell lung cancer (NSCLC): Prespecified subgroup analysis of the ATORG-003 trial.

Author

Tan, A., Kim, D-W., Baisamut (Reungwetwattana), T., Yueh Ni, L., Ho, G.F., Tho, L.M., Prasongsook, N., Lee, S., Mok, T.S.K., Tan, D.S.W., and Loong, H.H.F.

Subjects
*NON-small-cell lung carcinoma, *EPIDERMAL growth factor receptors, *SUBGROUP analysis (Experimental design)
Published
2022
Full Text
View/download PDF

16. 326P Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y).

Author

Cho, B.C., Luft, A., Alatorre Alexander, J.A., Lucien Geater, S., Laktionov, K., Sang-We, K., Ursol, G., Hussein, M., Lim Farah, L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E.B., Mok, T.S.K., and Johnson, M.L.

Subjects
*OVERALL survival, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

17. LBA59 Durvalumab (D) ± tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: Overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y).

Author

Johnson, M., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Laktionov, K., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C.T., Araujo, L.H., Saito, H., Reinmuth, N., Lai, Z., Mann, H., Shi, X., Peters, S., Garon, E., and Mok, T.S.K.

Subjects
*OVERALL survival, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

19. 5MO Patient reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON.

Author

Garon, E.B., Cho, B.C., Luft, A., Alatorre-Alexander, J., Geater, S.L., Trukhin, D., Kim, S-W., Ursol, G., Hussein, M., Lim, F.L., Yang, C-T., Araujo, L.H., Saito, H., Reinmuth, N., Medic, N., Mann, H., Shi, X., Peters, S., Mok, T.S.K., and Johnson, M.

Subjects
*PATIENT reported outcome measures, *NON-small-cell lung carcinoma, *CANCER chemotherapy, *METASTASIS
Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results